Payment overview · 2025
General Payments
$854.93
23 reported records · 6 companies
Healthcare provider profile · identity verified
Alexandra Marrs Bowling, DO
Allopathic & Osteopathic Physicians|Family Medicine · BRISTOL, VA · NPI 1073996948
Verified facts
What the public records show
CMS Open Payments records show Alexandra Marrs Bowling, DO received $854.93 in general payments during 2025 across 23 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 69.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Nuedexta by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $596.97 | 69.8% | 18 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $109.59 | 12.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $91.76 | 10.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.33 | 2.5% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $18.67 | 2.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.61 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $661.95 | 21 |
| Education | $192.98 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $403.99 | 16 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $109.59 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $91.76 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
93 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 1530 | 93 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1340 | 131 |
| Furosemide | Furosemide | 1306 | 105 |
| Omeprazole | Omeprazole | 981 | 135 |
| Levothyroxine Sodium | Levothyroxine Sodium | 911 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 791 | 88 |
| Trazodone Hcl | Trazodone Hcl | 714 | 89 |
| Potassium Chloride | Potassium Chloride | 698 | 78 |
| Lisinopril | Lisinopril | 560 | 71 |
| Gabapentin | Gabapentin | 497 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 475 | 69 |
| Carvedilol | Carvedilol | 432 | 58 |
| Mirtazapine | Mirtazapine | 427 | 59 |
| Sertraline Hcl | Sertraline Hcl | 372 | 39 |
| Donepezil Hcl | Donepezil Hcl | 370 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 343 | 34 |
| Buspirone Hcl | Buspirone Hcl | 318 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 307 | 32 |
| Ropinirole Hcl | Ropinirole Hcl | 306 | 22 |
| Losartan Potassium | Losartan Potassium | 304 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 293 | 33 |
| Memantine Hcl | Memantine Hcl | 282 | 26 |
| Metformin Hcl | Metformin Hcl | 266 | 26 |
| Baclofen | Baclofen | 259 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 256 | 31 |
| Jardiance | Empagliflozin | 245 | 17 |
| Sucralfate | Sucralfate | 245 | 20 |
| Tramadol Hcl | Tramadol Hcl | 210 | 32 |
| Ondansetron Hcl | Ondansetron Hcl | 198 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 196 | 36 |
| Hydralazine Hcl | Hydralazine Hcl | 189 | 23 |
| Amiodarone Hcl | Amiodarone Hcl | 184 | 17 |
| Levetiracetam | Levetiracetam | 167 | 20 |
| Torsemide | Torsemide | 166 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 159 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 154 | 28 |
| Allopurinol | Allopurinol | 151 | 17 |
| Simvastatin | Simvastatin | 145 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 143 | 18 |
| Ceftriaxone | Ceftriaxone Sodium | 139 | 74 |
| Lidocaine Hcl | Lidocaine Hcl | 138 | 74 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 136 | 39 |
| Fluoxetine Hcl | Fluoxetine Hcl | 131 | 13 |
| Divalproex Sodium | Divalproex Sodium | 128 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 127 | 22 |
| Midodrine Hcl | Midodrine Hcl | 123 | 22 |
| Metformin Hcl Er | Metformin Hcl | 115 | 11 |
| Prednisone | Prednisone | 114 | 32 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 102 | 15 |
| Brilinta | Ticagrelor | 101 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 97 | 11 |
| Sodium Chloride | 0.9 % Sodium Chloride | 95 | 54 |
| Entresto | Sacubitril/Valsartan | 94 | suppressed |
| Lorazepam | Lorazepam | 94 | 27 |
| Xarelto | Rivaroxaban | 94 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 93 | suppressed |
| Budesonide | Budesonide | 90 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 88 | suppressed |
| Gemtesa | Vibegron | 88 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 86 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 86 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 86 | 11 |
| Levofloxacin | Levofloxacin | 81 | 42 |
| Nystatin | Nystatin | 73 | 25 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 70 | 45 |
| Ezetimibe | Ezetimibe | 69 | suppressed |
| Finasteride | Finasteride | 69 | 15 |
| Primidone | Primidone | 66 | suppressed |
| Bupropion Xl | Bupropion Hcl | 65 | suppressed |
| Clonazepam | Clonazepam | 64 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 63 | suppressed |
| Valsartan | Valsartan | 63 | suppressed |
| Enulose | Lactulose | 62 | suppressed |
| Celecoxib | Celecoxib | 61 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 59 | 14 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 57 | 57 |
| Atenolol | Atenolol | 57 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 57 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 57 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 55 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 54 | 16 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 54 | suppressed |
| Myrbetriq | Mirabegron | 54 | suppressed |
| Pregabalin | Pregabalin | 54 | suppressed |
| Austedo | Deutetrabenazine | 53 | suppressed |
| Fluconazole | Fluconazole | 52 | 37 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 52 | suppressed |
| Hydrocortisone | Hydrocortisone | 52 | 14 |
| Phenelzine Sulfate | Phenelzine Sulfate | 52 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 50 | suppressed |
| Amoxicillin | Amoxicillin | 48 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 48 | suppressed |
| Savella | Milnacipran Hcl | 47 | suppressed |
| Trulicity | Dulaglutide | 47 | suppressed |
| Multaq | Dronedarone Hcl | 46 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 23 |
| Diltiazem 24hr Er | Diltiazem Hcl | 45 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 45 | 19 |
| Alprazolam | Alprazolam | 44 | suppressed |
| Bumetanide | Bumetanide | 43 | suppressed |
| Cefdinir | Cefdinir | 43 | 31 |
| Nuplazid | Pimavanserin Tartrate | 43 | suppressed |
| Topiramate | Topiramate | 43 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 42 | suppressed |
| Azithromycin | Azithromycin | 42 | 19 |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Cephalexin | Cephalexin | 41 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 27 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | suppressed |
| Sulfasalazine | Sulfasalazine | 41 | suppressed |
| Olanzapine | Olanzapine | 40 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 39 | suppressed |
| Latanoprost | Latanoprost | 39 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | suppressed |
| Ranolazine Er | Ranolazine | 37 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 36 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 36 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 21 |
| Spironolactone | Spironolactone | 36 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 36 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 35 | 18 |
| Nyamyc | Nystatin | 35 | 13 |
| Lamotrigine | Lamotrigine | 34 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 33 | suppressed |
| Ertapenem | Ertapenem Sodium | 33 | 15 |
| Meloxicam | Meloxicam | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 32 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 30 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 30 | suppressed |
| Febuxostat | Febuxostat | 29 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 27 | 17 |
| Diazepam | Diazepam | 27 | suppressed |
| Estradiol | Estradiol | 27 | 11 |
| Colestipol Hcl | Colestipol Hcl | 26 | suppressed |
| Lubiprostone | Lubiprostone | 26 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 26 | suppressed |
| Metolazone | Metolazone | 26 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 26 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 26 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 26 | 12 |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Methylprednisolone Acetate | Methylprednisolone Acetate | 25 | 21 |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Rivastigmine | Rivastigmine | 24 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Entacapone | Entacapone | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | 12 |
| Santyl | Collagenase Clostridium Hist. | 22 | 11 |
| Meropenem | Meropenem | 21 | 13 |
| Sodium Chloride | Sodium Chloride 0.45 % | 21 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | suppressed |
| Dexamethasone | Dexamethasone | 20 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 19 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Nystop | Nystatin | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Linezolid | Linezolid | 17 | 11 |
| Loxapine | Loxapine Succinate | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Budesonide Ec | Budesonide | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Mesalamine | Mesalamine | 15 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 15 | 15 |
| Roflumilast | Roflumilast | 15 | suppressed |
| Xifaxan | Rifaximin | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 14 | 12 |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 14 | suppressed |
| Solu-Medrol | Methylprednisolone Sod Succ/Pf | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 13 | suppressed |
| Leflunomide | Leflunomide | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 12 | suppressed |
| Lactated Ringers | Ringer's Solution,lactated | 12 | 11 |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | 11 |
| Sps | Sodium Polystyrene Sulfon/Sorb | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $854.93 · 23 records | Teva Pharmaceuticals USA, Inc. | AUSTEDO XR, Auvelity, INGREZZA, Nayzilam, Ozempic, REXULTI, Rybelsus | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Otsuka America Pharmaceutical, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error